AstraZeneca Expands Immuno-Oncology Collaboration with Innate Pharma

By Jasmine Kalsi & Michelle Liu

Pharma Deals Review: Vol 2018 Issue 11 (Table of Contents)

Published: 30 Nov-2018

DOI: 10.3833/pdr.v2018.i11.2374     ISSN: 1756-7874

Section: Research & Development



Revitalising its immuno-oncology portfolio, AstraZeneca (AZ) has expanded its 2015 research collaboration with Innate Pharma following promising Phase II data, in to a three-part deal that will see AZ hand over US$170 M in opt-in and upfront payments and commit up to US$5...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details